Assertio Holdings ISIN: US04546C2052 Forum: Aktien User: Summer.76
0,8859 USD
+5,09 %+0,0429
21. Dec, 02:00:00 Uhr,
Nasdaq
Kommentare 36
Summer.76,
22.01.2023 15:15 Uhr
0
https://seekingalpha.com/article/4571315-assertio-holdings-scores-with-new-broadly-covered-asset
Assertio Holdings Scores With New Broadly-Covered Asset
Summary
• Assertio Holdings, Inc. got the rights to Sympazan in October.
• Most Medicare plans cover it.
• Meanwhile, Assertio Holdings, Inc.'s lead product Indocin is a favored brand by the nation's #1 health insurance company.
...
Summer.76,
10.01.2023 16:56 Uhr
0
https://www.globenewswire.com/news-release/2023/01/09/2585674/0/en/Assertio-Holdings-Inc-Announces-FDA-Orange-Book-Listing-for-New-Sympazan-Oral-Film-Patent.html
Summer.76,
13.12.2022 21:01 Uhr
0
https://investor.assertiotx.com/news/news-details/2022/Assertio-Holdings-Inc.-to-Host-Investor-and-Business-Development-Meetings-January-9-11-2023-in-San-Francisco/default.aspx
Summer.76,
05.12.2022 16:21 Uhr
0
https://finance.yahoo.com/news/assertio-increases-full-net-product-123000490.html
Summer.76,
09.11.2022 5:40 Uhr
0
Assertio Reports Third Quarter 2022 Financial Results
https://finance.yahoo.com/news/assertio-reports-third-quarter-2022-210100129.html
Net Product Sales Increase 32% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases 36%
Increases Guidance for Net Product Sales and Adjusted EBITDA
Debt Refinancing Extends Maturity, Reduces Cost and Increases Strategic Flexibility
Expects Sympazan to Add $1 Million in Net Product Sales in 4Q
Summer.76,
27.10.2022 17:49 Uhr
0
Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc.
https://www.globenewswire.com/news-release/2022/10/27/2542885/0/en/Assertio-Holdings-Inc-Signs-Exclusive-License-for-Sympazan-clobazam-Oral-Film-from-Aquestive-Therapeutics-Inc.html
Trailing 12 Month Revenues of Sympazan Were $9.5 Million
Assertio Paid $9.0 Million Upfront, Additional $6.0 Million upon Patent Allowance
Summer.76,
25.08.2022 16:53 Uhr
0
https://www.globenewswire.com/news-release/2022/08/25/2504787/0/en/Assertio-Announces-Closing-of-70-Million-Convertible-Senior-Notes-Offering.html
Summer.76,
22.08.2022 22:54 Uhr
0
https://www.globenewswire.com/news-release/2022/08/22/2502498/0/en/Assertio-Announces-Proposed-Convertible-Senior-Notes-Offering-to-Refinance-Existing-13-Senior-Secured-Notes-Due-2024.html
Summer.76,
08.08.2022 16:17 Uhr
0
Assertio: Q2 Earnings Snapshot
https://amp.centredaily.com/news/business/article264283891.html
Summer.76,
08.08.2022 16:16 Uhr
0
ASSERTIO REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
https://investor.assertiotx.com/news/news-details/2022/Assertio-Reports-Second-Quarter-2022-Financial-Results/default.aspx
Net Product Sales Increase 40% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases to $22.9 million
Raises Full Year Revenue and Non-GAAP Adjusted EBITDA Guidance
...
Summer.76,
10.06.2022 20:22 Uhr
0
Assertio Holdings: Management Still Swimming Against The Tide
https://seekingalpha.com/article/4517731-assertio-holdings-management-still-swimming-against-the-tide
Summary
• In a note 12 months ago I told the story of how Assertio, formerly DepoMed, nearly went under after its disastrous acquisition of opioid drug Nucynta.
• A new management team was able to dispose of the asset, settle debts, and acquire a portfolio of NSAIDs, which have driven exceptional cash flow.
• The forecast for 2022 is for $126-136m of revenues and EBITDA of $64-72m.
• That's remarkable, but it may obscure the fact that sales volumes of lead asset Indocin appear to be shrinking and there's limited scope for new product acquisitions.
• It's a tough ask for management to keep Assertio afloat in a sea of troubles caused by opioid exposure and litigation. Approach with caution.
...
Summer.76,
10.05.2022 5:45 Uhr
0
Assertio Therapeutics Non-GAAP EPS of $0.38, revenue of $36.54M beats by $3.48M
https://seekingalpha.com/news/3835430-assertio-therapeutics-non-gaap-eps-of-0_38-revenue-of-36_54m-beats-3_48m
• Assertio Therapeutics press release (NASDAQ:ASRT): Q1 Non-GAAP EPS of $0.38.
• Revenue of $36.54M (+36.1% Y/Y) beats by $3.48M.
• 2022 Financial Guidance
• Net Product Sales (GAAP): $126.0 Million to $136.0 Million
• Adjusted EBITDA (Non-GAAP): $66.0 Million to $74.0 Million
Summer.76,
10.05.2022 5:40 Uhr
0
Assertio Reports First Quarter 2022 Financial Results
https://www.globenewswire.com/news-release/2022/05/09/2439008/0/en/Assertio-Reports-First-Quarter-2022-Financial-Results.html
Reaffirms Full Year Net Product Sales and Raises Full Year Non-GAAP Adjusted EBITDA Guidance
Net Product Sales Up 37% and Non-GAAP Adjusted EBITDA Up 52% Compared to Prior Year Quarter
Quarterly Net Cash Flows from Operating Activities of $27.4 Million
Summer.76,
07.04.2022 20:08 Uhr
0
Assertio Holdings: Recent Breakout To Lead To Sustained Gains
https://seekingalpha.com/article/4500271-assertio-holdings-recent-breakout-leading-to-sustained-gains
Summary
• Company grows the top-line by 7% in Q4 due to strong performances from Indocin, Cambia & Zipsor.
• Promising guidance eventually led to a breakout above the January highs.
• We look at Assertio's profitability and valuation metrics to see if the breakout has merit.
...
Vancouver,
05.04.2022 19:09 Uhr
0
ganz allein hier -Summer - gute performence die Monate - hat hier niemand aufm Schirm-
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | Trading- und Aktien-Chat | ||
2 | MicroStrategy | ±0,00 % | |
3 | Wonderfi Technologies Inc Hauptforum | ±0,00 % | |
4 | für alle, die es ehrlich meinen beim Traden. | ||
5 | Hut 8 Mining | ±0,00 % | |
6 | TradingBulls | ||
7 | DRONESHIELD LTD Hauptdiskussion | ±0,00 % | |
8 | JINKOSOLAR Hauptdiskussion | ±0,00 % | |
9 | MICROSTRATEGY Hauptdiskussion | ±0,00 % | |
10 | PAYPAL Hauptdiskussion | ±0,00 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | MicroStrategy | ±0,00 % | |
2 | Wonderfi Technologies Inc Hauptforum | ±0,00 % | |
3 | Hut 8 Mining | ±0,00 % | |
4 | DRONESHIELD LTD Hauptdiskussion | ±0,00 % | |
5 | JINKOSOLAR Hauptdiskussion | ±0,00 % | |
6 | MICROSTRATEGY Hauptdiskussion | ±0,00 % | |
7 | PAYPAL Hauptdiskussion | ±0,00 % | |
8 | VONOVIA Hauptdiskussion | +0,10 % | |
9 | EVOTEC Hauptdiskussion | +0,12 % | |
10 | AMD Hauptdiskussion | -0,03 % | Alle Diskussionen |